Todo parece indicar que estamos ante la repeticion de lo que antes sucedio. Ya hay bastantes acusaciones en lo foros al respecto con un tal Brancaccio que forma parte de a directiva y tiene varios antncedentes
Synergy Shares Climb After Manipulation Arrests
Jun. 4, 2015 7:30 PM ET
Eur/USD
1,127,
rompió soporte en 1.13
leches... yo pensaba que despues de las elecciones cambaria el rumbo, para mi bien que tengo una cuenta con dolores... :)
26 en pre, comienza fuerte. Me esperaba que le metieran algún corto de entrada para tratar de frenarla pero de momento sigue su inercia.Saludos
AMRN
Edito: muchas oscilaciones. Ahora por debajo de 24
futuros no buenos
TSRO
Algo de info sobre la subida a 900mg, no entiendo la implicación exacta pero parece que la mejora no sería mucha en base a datos pasados:
https://twitter.com/biotechinvstr/status/1061965896095272960?s=19
Jeeejem ......MUCHO HABIA DEMORADO
Amarin down 14% premarket on scrutiny of REDUCE-IT study
Nov. 12, 2018 8:51 AM ET|About: Amarin Corporation PLC (AMRN)|By: Douglas W. House, SA News Editor
Amarin (NASDAQ: AMRN) is off 14% premarket on robust volume in apparent reaction to the details of REDUCE-IT, the large-scale study showing the cardiovascular benefits of Vascepa (icosapent ethyl) in statin-treated patients with triglyceride levels between 135 mg/dL and 499 mg/dL, a much larger potential patient population than its current labeling allows.
SA Contributor DoctoRx has published an insightful article on the REDUCE-IT data, including suspicions that the placebo group received mineral oil which could affect the absorption of statins. This "anti-statin" effect could raise "bad cholesterol" levels, enhancing the separation of major adverse cardiac events (MACE) between Vascepa and control.
Previously: Amarin's Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study (Nov. 11)
ZIOP
Ziopharm up 2% premarket on $50M capital raise and advancement of Ad-RTS-hIL-12
The company has secured $50M in new capital via the direct sale of stock and warrants to a group of investors led by MSD Partners, L.P. The company will issue ~18.9M common shares and warrants to purchase up to the same number of shares at a combined price of $2.64 per share and warrant. The five-year warrants are exercisable at $3.01 per common share. The transaction should close by November 13. Friday's close was $2.51.
Ziopharm Oncology (ZIOP) Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
«Después de nada, o después de todo/ supe que todo no era más que nada.»
